Drug intelligence / Profile preview

lutetium-177-dotaga-iac

Development stage: Unknown
Lead developer: Iason
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

Lutetium-177-dotaga-iac is an investigational radiopharmaceutical designed for targeted radionuclide therapy of tumors expressing the αvβ3 integrin, which is associated with angiogenesis. The compound consists of the radioactive isotope lutetium-177 chelated to DOTAGA-IAC, a molecule that targets αvβ3 integrin on tumor cells. Upon binding to its target, the radiolabeled agent delivers localized beta radiation to tumor tissue, causing cellular damage and death while sparing most normal tissues. Preclinical studies have demonstrated high radiolabeling yield and rapid clearance from non-target tissues. Clinical trials are ongoing in patients with unresectable angiogenic breast cancer as a second or third-line treatment[2][4][5].

Brand names: HurlutinTM Lu-177
Other names: Lu-177-DOTAGA-IACLu177-DOTAGA-IACLu 177-DOTAGA-IAC177Lu-DOTAGA-IAC

Targets

αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on lutetium-177-dotaga-iac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium-177-dotaga-iac.

Explore the full profile